Inventor
RIXON MARK W
US40 patents
⚠️ This page may combine multiple inventors who share the name “RIXON MARK W”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ZYMOGENETICS INC
19 patentsUS7501497B2Mar 10, 2009
TACI-immunoglobulin fusion proteins
ZYMOGENETICS INC32 citations96
US7635767B2Dec 22, 2009
Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the same
ZYMOGENETICS INC14 citations93
US7122632B2Oct 17, 2006
Soluble Interleukin-20 receptor
ZYMOGENETICS INC20 citations92
US9346878B2May 24, 2016
Methods of treating glomerulonephritis associated with IGA nephropathy for TACI-immunoglobulin fusion proteins
ZYMOGENETICS INC4 citations84
US7951919B2May 31, 2011
TACI-immunoglobulin fusion proteins
ZYMOGENETICS INC7 citations84
US7862814B2Jan 4, 2011
Method of inhibiting the proliferation of B cell cancers using TACI-immunoglobulin fusion proteins
ZYMOGENETICS INC7 citations84
US7842665B2Nov 30, 2010
IL-17A and IL-17F antagonists
ZYMOGENETICS INC11 citations84
US7622116B2Nov 24, 2009
Method of treating inflammation using soluble IL-17RCX4
ZYMOGENETICS INC10 citations84
US8815238B2Aug 26, 2014
Methods for Preparing TACI-immunoglobulin fusion proteins
ZYMOGENETICS INC3 citations74
US7964711B2Jun 21, 2011
Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the same
ZYMOGENETICS INC6 citations74
US6329175B1Dec 11, 2001
Interferon-ε
ZYMOGENETICS INC12 citations74
US7585948B2Sep 8, 2009
Soluble interleukin-20 receptor
ZYMOGENETICS INC2 citations62
US7387780B2Jun 17, 2008
Soluble interleukin-20 receptor
ZYMOGENETICS INC2 citations62
US8361470B2Jan 29, 2013
Methods of treatment using anti-human IL-21 monoclonal antibodies
ZYMOGENETICS INC1 citations61
US7883700B2Feb 8, 2011
Anti-human IL-21 monoclonal antibodies
ZYMOGENETICS INC3 citations61
US7790676B2Sep 7, 2010
Soluble IL-17RA/RC fusion proteins
ZYMOGENETICS INC3 citations60
US6544505B2Apr 8, 2003
Interferon-epsilon
ZYMOGENETICS INC0 citations52
US10570187B2Feb 25, 2020
Soluble hybrid Fcγ receptors and related methods
ZYMOGENETICS INC0 citations50
US9663566B2May 30, 2017
Soluble hybrid Fcγ receptors and related methods
ZYMOGENETICS INC0 citations50
DOW CHEMICAL CO
6 patentsUS5472693ADec 5, 1995
Family of anti-carcinoembryonic antigen chimeric antibodies
DOW CHEMICAL CO86 citations96
US5993813ANov 30, 1999
Family of high affinity, modified antibodies for cancer treatment
DOW CHEMICAL CO26 citations92
US6207815B1Mar 27, 2001
Family of high affinity, modified antibodies for cancer treatment
DOW CHEMICAL CO15 citations83
US6051225AApr 18, 2000
Family of high affinity, modified antibodies for cancer treatment
DOW CHEMICAL CO10 citations73
US5808033ASep 15, 1998
Family of anti-carcinoembryonic antigen chimeric antibodies
DOW CHEMICAL CO11 citations73
US6641999B1Nov 4, 2003
Probing method for identifying antibodies specific for selected antigens
DOW CHEMICAL CO2 citations57
BRISTOL MYERS SQUIBB CO
6 patentsUS8945553B2Feb 3, 2015
Bispecific antibodies to IL-23 and IL-17A/F
BRISTOL MYERS SQUIBB CO16 citations91
US9708401B2Jul 18, 2017
IL-17A/F cross-reactive monoclonal antibodies and methods of using the same
BRISTOL MYERS SQUIBB CO3 citations84
US11254740B2Feb 22, 2022
Methods of treatment using IL-23p19 monoclonal antibodies
BRISTOL MYERS SQUIBB CO0 citations62
US9783606B2Oct 10, 2017
Polynucleotides encoding IL-17/IL-23 bispecific, IL-17A/F and IL-23p19 antibodies
BRISTOL MYERS SQUIBB CO1 citations61
US10358489B2Jul 23, 2019
IL-23p19 monoclonal antibodies
BRISTOL MYERS SQUIBB CO0 citations52
US10358490B2Jul 23, 2019
Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodies
BRISTOL MYERS SQUIBB CO0 citations51